Metastatic melanoma is hallmarked by its ability to switch oncogenic MITF expression. Here we tested the impact of STAT3 on melanoma onset and progression in association with MITF expression levels. We established a mouse melanoma model for deleting Stat3 specifically in melanocytes with specific expression of human hyperactive NRAS Q61K in an Ink4a deficient background. Mice with tissue specific Stat3 deletion showed an early onset of disease, but displayed significantly diminished lung metastases. Whole genome expression profiling also revealed a reduced invasion phenotype, which was functionally confirmed in 3D melanoma model systems. Notably, loss or knockdown of STAT3 in mouse or human cells resulted in upregulation of MITF and induction of cell proliferation. Mechanistically we show that STAT3 induced CEBPa/b expression was sufficient to suppress MITF transcription. Epigenetic analysis by ATAC-seq confirmed that STAT3 enabled CEBPa/b binding to the MITF enhancer region thereby silencing it. We conclude that STAT3 is a metastasis driver in melanoma able to antagonize the MITF oncogene via direct induction of CEBP family member transcription facilitating RAS-RAF-driven melanoma metastasis. Authorship note: R. Moriggl and M. Mikula contributed equally to this work. Initial design and work was performed by RM, MM and AS. RS, AS, MM and RM wrote the original draft of the manuscript. RS and AS designed, performed and analyzed experiments. MV performed in vitro 3D proliferation and invasion experiments. KK performed in vitro migration experiments and quantified xenograft and evaluated patient TMA stainings. BW, HTTP, RZ and BK helped designing experiments and provided major technical support. JH performed and analyzed xenograft experiments. CS and FA performed shRNA knockdown. DSc, AFR and TK analyzed in silico ATAC-seq or melanoma patient data. PP provided and stained human melanoma TMAs. SK and TK significantly assisted in data analysis. DSt, LK, LL, VP, FB, TY, SK, FA and MH reviewed and edited the manuscript. All authors have given approval to the final version of the manuscript.
Introduction
Melanoma is a very aggressive form of skin cancer, with >76.000 new cases diagnosed annually in the US 1 . Stage I and stage II lesions can be successfully removed by surgery, but metastasized melanomas are challenging to treat, leading to an estimated 10.000 deaths in the US annually 1 . The current prognosis of advanced melanoma remains poor despite the success of immune-and targeted therapy 2 . This phenomenon can be attributed to the plasticity of melanoma, which describes the ability of melanoma cells to switch multiple times from a proliferative to an invasive state without the need for additional mutations 3, 4 . A key player involved in phenotype switching of melanoma is the Microphthalmia-associated Transcription Factor (MITF). MITF is essential for melanocyte development, homeostasis and pigmentation response 5, 6 . This oncoprotein controls differentiation, survival and proliferation.
High MITF expression marks melanoma cells with a proliferative, but non-invasive phenotype.
In contrast, melanoma cells expressing low MITF protein represent increased invasive and metastatic capacity 3, [7] [8] [9] . Overall, the regulation of MITF by NRAS and BRAF oncogenes in context of STAT3 signaling is unclear 7, 10 .
Interestingly, about 50% of melanoma patients display prominent and enhanced tyrosine phosphorylation of Signal Transducer and Activator of Transcription 3 (STAT3) catalyzed via JAK, SRC or growth factor tyrosine kinase family members [11] [12] [13] [14] . So far, reports on inhibition of STAT3 by siRNA or expression of a dominant negative form of STAT3 in xenograft models have postulated an oncogenic role of STAT3 in melanoma progression, but detailed genetic studies are still missing 12, 15 . Contrary, treatment with Oncostatin M (OSM) or IL-6 resulted in phosphotyrosine-mediated STAT3 (pYSTAT3) activation and decreased proliferation in melanoma cell line studies, suggesting a tumor suppressor role for STAT3 in melanoma progression 14, 16 . In prostate, lung and colorectal carcinomas, tumor suppressive roles were associated with STAT3 function depending on the mutational context or STAT1 expression levels, a known heterodimerization partner/balancer of oncogenic STAT3 [17] [18] [19] [20] . A specific role for STAT3 in melanoma has not yet been established and it is not clear whether STAT3 plays a role in phenotype-switching towards invasive melanoma.
Here, we utilized a genetic model of spontaneous melanoma formation. To closely mimic human melanoma, transgenic mice have been used carrying melanocyte-specific expression of the NRAS Q61K oncogene in an INK4A-deficient background 21 . Additionally, the mouse model allows for conditional melanocyte-specific deletion of Stat3 22 . We show that melanoma lacking Stat3 expression have an accelerated tumor onset in vivo and exert higher proliferation rate. In contrast, metastasis formation from Stat3 knockout primary tumors was severely impaired. STAT3 function was evaluated mechanistically using tumor derived cell lines, where we performed whole genome expression analysis combined with ATAC-seq profiling. We found, that STAT3 antagonizes MITF expression through elevated expression of CAAT Box Enhancer Binding Protein (CEBP) family members. Remarkably, data mining of melanoma patient samples also revealed a negative correlation of CEBPa/b with MITF. STAT3 knockdowns in human melanoma confirmed these observations. We conclude that STAT3 is associated with melanoma metastasis and MITF is associated with melanoma growth. Therefore, concurrent low STAT3 and high MITF expression marks worsened prognosis for melanoma patients.
Results

Loss of STAT3 enhanced pigmentation, enabled earlier tumor onset, but reduced metastasis
To study the effect of STAT3 loss in melanoma we used a mouse model that allows the (Fig. 1 A) . Melanocyte specific CRE expression was described to recombine loxP sites from E10.5 onwards in development 23 . Hence, STAT3 was lost in mouse skin melanomas as evaluated by immunohistochemistry (IHC, Fig. 1 B) . PCNA staining revealed that primary Stat3 ∆ tumors displayed increased cell cycle activity compared to Stat3 fl tumors ( Fig. 1 C) . In line with this, we observed significantly accelerated tumor onset in the Stat3 Next, lungs of 40 week old mice were stained for S100b to visualize micrometastases. Importantly, Stat3 deletion significantly reduced the overall number of metastatic lung colonies ( Fig. 1 F) . These findings indicate that albeit tumor growth was accelerated in the Stat3 ∆ group, Stat3 expression enhanced the metastatic process. Next, we investigated the mechanism responsible for reduced metastasis of Stat3 ∆ melanomas.
Expression profiling revealed MITF pathway induction upon loss of STAT3
We isolated tumor cells from melanoma positive lymph nodes of the Stat3 fl and Stat3 ∆ mice and selected for melanoma cells by continuous culturing for 10 passages. Cells were uniformly positive for the melanoma marker S100b (Fig. S1 D) . They showed basal or enhanced STAT3 activity after IL-6 stimulation, while Stat3 ∆ cells showed complete loss of STAT3 expression as measured by STAT3 tyrosine and serine phosphorylation using specific antibody detection by Western blotting (Fig. 2 A) . Then we performed Affymetrix whole transcriptome microarray mRNA analysis followed by gene set enrichment analysis (GSEA) under basal growth conditions or stimulation with murine IL-6 or OSM. Loss of Stat3 resulted in significant reduction of Stat3 target gene expression ( Fig. 2 B) . Importantly, Stat3 ∆ cells displayed augmented MITF pathway activation, which was amongst the top up-regulated pathways ( Fig. 2 B) . To our surprise, cytokine stimulation neither influenced the overall MITF pathway regulation by activated STAT3 (Fig. 2 C, D and Fig. S2 ), nor changed the overall gene expression after two hours of stimulation significantly. We conclude that low pYSTAT3 is actively engaged for broad Stat3 target gene transcription by oncogenic RAS-RAF signaling to reprogram melanoma cells, independent of a cytokine stimulus.
Invasion and EMT-like phenotype are suppressed upon loss of Stat3
Gene set enrichment analysis, including proliferative and invasive melanoma signatures, were performed to identify STAT3 related phenotypes ( Fig. 3 A) . We found that Stat3 ∆ cells resembled MITF-driven proliferative gene signatures, which were identified in two independent large melanoma cohort studies 3, 9 . In contrast, Stat3 fl cells are closely related to the described invasive signatures. Performing in vitro assays, we found enhanced 3Dproliferation, but abrogated invasion and migration in Stat3 higher cellular density and showed little to no invasion of epidermal tissue ( Fig. 3 D) . In contrast Stat3 fl -derived tumors were de-differentiated with fibroblastoid morphology and showed high invasion into murine epidermis. Tumor formation and growth rates of the two melanoma groups after xenotransplantation were comparable ( Fig. S3 A) .
Beside the prominent MITF pathway expression, we found a set of five important de-regulated receptor tyrosine kinases: Three of them, platelet-derived growth factor receptor alpha and beta (PDGFRa/b) and epidermal growth factor receptor (EGFR). These are known targets of 
Reciprocal expression between CEBPs and MITF
To investigate the mechanisms underlying the regulation of MITF by STAT3, we reasoned that STAT3 or its downstream targets could repress MITF. To test this hypothesis, we investigated regulatory elements of the proximal Mitf promoter region by ATAC seq. We found that Stat3 fl cells displayed chromatin accessibility in a regulatory element in close proximity of the Mitf gene which contained a CEBPa/b binding element ( Fig To test, whether our findings also apply for human melanoma cell lines, we performed stable lentiviral shRNA mediated knockdown of Stat3 in 451Lu, WM793B and WM35 cells. databases. This analysis revealed a strong negative correlation between MITF and CEBPA as well as between MITF and CEBPB expression ( Fig. 6 E) .
Validation of STAT3 expression signatures in human clinical samples
To assess the clinical relevance of the relationship between MITF and CEBPa/b, we performed Kaplan-Meier survival analysis on publicly available datasets (GEO accession GSE19234 and TCGA data from Cutaneous Melanoma). Samples were sorted according to the expression level of STAT3, CEBPA, CEBPB and MITF to generate equal sized low-and high-risk groups ( Fig. 7 A) . The high-risk group was defined by high levels of MITF in combination with low STAT3, CEBPA and CEBPB levels ( Fig. 7 B) . To validate our findings in human patient samples we analyzed a cohort of 25 primary melanoma tumors and 96-130 melanoma metastases for STAT3 and MITF antibody mediated staining intensities. Primary tumors compared to metastases showed higher levels of STAT3 protein, while MITF levels were higher in metastases than in primary tumors ( In summary, we conclude that expression of CEBP family members depends on availability of STAT3. Upon Stat3 deletion, Cebpa, Cebpb and Cebpd levels decreased, resulting in increased expression of Mitf, which abrogated invasion/migration and led to diminished metastasis formation ( Fig. 7 E) . In summary, the prognostic relevance is underlined by our findings that low STAT3 and high MITF expression exert a worsened prognosis for melanoma patients.
Discussion
We identified STAT3 as a critical regulator to promote melanoma progression in a NRAS- Hence, targeting of STAT3 in melanoma therapy would drive tumors towards the melanocytic lineage and it would enhance proliferation. Targeting STAT3 only, could result in a worsened outcome, but targeting both oncogenic MITF and STAT3 could be beneficial for patients since both transcription factors control melanoma biology. Recent data showed that MITF inversely regulated the amount of EGFR, which was important to establish Vemuravenib resistance 25 .
Our data confirm this inverse association since we show that STAT3 induced MITF repression lead to EGFR and PDGFR accumulation. These findings display that MITF and STAT3 are tightly interwoven, best exemplified by tyrosine kinase receptor expression changes. While PDGFRa/b and EGFR were down-regulated in the Stat3 ∆ group, MET and cKIT receptor showed strong up-regulation. These five receptor tyrosine kinases can all prominently activate STAT3 and their mode of action will depend on ligand-induced ligation via stromal components suggesting cell-cell interaction complexity, but also pointing towards the interdependence of the YIN/YANG STAT3/MITF dualism. MET and cKIT receptors are described as target genes of MITF and they could facilitate melanoma growth, invasion and angiogenesis 26, 27 . In addition, MET expression was associated with dependency of melanoma cells with a malignant phenotype 28 . High cKIT levels are frequently found in benign skin lesions and primary melanomas associated with a less invasive phenotype 29 . These reports support our finding that high MITF activity results in faster proliferation of melanomas to suppress migration and invasion. Interestingly, PDGFR expression in epithelial cells can be regarded as a marker for the EMT phenotype 30, 31 . The low response rate of patients towards anti-melanoma therapy was attributed to the persistence of a pronounced EMT-like phenotype 32, 33 . This could be due to the fact, that EMT in tumor patients is considered as a major factor in the development of resistance towards tyrosine kinase blockers 34 and for escaping PD-1 immunotherapy treatment 35 . Our conclusion regarding STAT3 as a metastasis driver is paralleled by recent reports which describe STAT3 activity in melanoma cells as a driver for up-regulation of invasion-related genes and as a major factor in the transition towards a mesenchymal phenotype during EMT-like processes 36 . Consistently, STAT3 inhibition was shown to reduce invasion and migration of cells 12, 37 . Since Stat3 Nuclear Antigen (PCNA) and Cyclin D1 43, 44 . This indicates, that patient survival times in melanoma are not determined by the degree of invasiveness, but rather by the amount of proliferation.
Our findings imply that STAT3 is a vulnerable node for fighting melanoma migration and invasion. We provide a rationale for clinical exploration of MITF inhibitors in combination with STAT3 inhibition, since MITF high expression is associated with poor survival. Importantly, here we identified STAT3 as a critical regulator of the MITF pathway, which has been recently shown to be the key pathway activated after acquired resistance to mitogen-activated protein kinase (MAPK)-targeted therapy 45, 46 . We conclude that a balanced YIN/YANG expression of STAT3/MITF controls melanoma fate and we propose that the main role of STAT3 is to promote invasion and metastatic spread. 
Materials and Methods
Animals and generation of transgenic mice
Xenograft experiments
A total of 1×10 6 cells were injected into the left and right flank of 8-10 weeks old NSG mice.
Tumor volumes were evaluated every 48 hours by measuring two perpendicular diameters with calipers. Tumor volume was calculated using the following equation:
(width*width*length)/2. The experiment was stopped when tumors exceeded a calculated size of 600 mm³.
Cell lines
Mouse melanoma cell lines were established from lymph nodes of diseased mice (25-30 Murine OSM (20 ng/ml) was purchased from R&D. For transfection of murine melanoma cells, the cells were seeded in 6-well plates and starved overnight in 2% DMEM without antibiotics.
Cells were transfected with 2 µg CEBPa, CEBPb or STAT3ER T2 plasmid using lipofectamine 3000 (Invitrogen) according to the manufacturer's protocol and analyzed after 24 hours. After transfection, the cells carrying the STAT3ER T2 plasmid 24 were selected for four weeks in 1 µg/ml puromycin (Sigma) and expression was tested by Western blot (Fig. S3 C) . spheroids, each consisting of 2.500 melanoma cells were formed in a 96 well round bottom plate. After four days of formation the spheroids were embedded into a 3D rattail-collagen matrix and grown in DMEM for 20 hours. Invasion was evaluated as described by 49 . For the in vitro cell migration assay 3×10 4 cells were seeded in serum free DMEM onto 8 µm pore transwell inserts (BD Biosciences). As attractant DMEM containing 10% FBS was used. Cells were allowed to migrate 8 hours, then the cells were fixed with 4% formaldehyde, the cells on the upper side of the transwell were wiped away and migrated cells were stained with 0.1% crystal violet (all from Sigma). Six fields of view were taken with microscope images using a 10x magnification with cell counting.
3D proliferation and in vitro migration assays
RNA interference and lentiviral transduction
RNA interference and lentiviral transduction experiments were performed as described in 50 .
The following shRNA constructs selected from the Mission TRC shRNA library (Sigma) were used: shRNA STAT3 (TRCN0000071456) and scrambled control shRNA (SHC002).
Transduced cells were selected for puromycin resistance prior to further analysis. The functionality of shRNAs was validated by realtime-PCR and Western blot analysis using antibodies listed in Table S3 .
RNA isolation and real-time PCR
RNA was isolated by TriZol (Life Technologies) extraction. Complementary DNA transcription was performed by RevertAid™ H Minus First Strand cDNA Synthesis Kit (Fermentas)
according to the manufacturer's instruction. Primer pairs are listed in Table S1 . Real-time PCR was performed in triplicates on a RealPlex Master-cycler (Eppendorf). Values were normalized to either murine or human ACTB mRNA expression. Results were quantified using the Delta C(T) method 51 .
Western blotting
Protein lysates, SDS-PAGE and Western blotting were performed according to standard protocols. Nitrocellulose membranes (Amersham) were incubated with antibodies listed in Table S3 . Semi-quantitative densitometric analysis of bands was performed with the ImageJ software according to standard procedures.
Melanin absorption assay
Absorption of Melanin in mouse melanoma cells was measured at 410 nm in an Infinite
Nanoquant photometer (Tecan) using the supernatant of 5x10 5 cells 48 hours after seeding.
Two biological replicates with six independent measurements were performed.
Immunohistochemistry, immunofluorescence and tissue microarrays
Mouse tissue was fixed overnight in 4% phosphate buffered formaldehyde solution, dehydrated, paraffin embedded and cut. 3-µm-FFPE tissue sections were stained with Hematoxylin (Merck) and Eosin G (Roth). Immunohistochemistry and immunofluorescence was performed using antibodies listed in Table S2 . For immunohistochemical analysis of cutaneous mouse melanomas, tissue microarrays were built including 28 cutaneous melanomas and 28 positive lymph nodes, each represented by duplicate core biopsies.
Normal skin and lymph nodes served as controls. For quantification, high-power field sections (x200 objective) were obtained for each sample and analyzed with HistoQuest (TissueGnostics) ( Fig. 1 B and C, Fig. S1 B) quantification software or Tissue Studio Software ® (Definiens) ( Fig. 4 B and 7 C) as described 52, 53 . In brief, cut-offs (to differentiate between positive and negative cells) were set for all samples and the resulting positive intensities were normalized to Hemalaun staining intensity. Images were taken with a Zeiss Imager Z1 microscope. Immunofluorescence images were taken with a Leica TCS SP8 Microscope.
Immunocytochemistry
To characterize murine cells as melanoma cells, they were trypsinized and 2x10 5 cells were centrifuged using the Thermo Scientific Shandon Cytospin (Shandon Scientific). The samples were fixed in methanol (10', -20°C) and dried for one hour at room temperature. Samples were stained by S100b by standard methods (Fig. S1 B, Table S2 ). For immunofluorescence staining on murine melanoma cells, 1.5x10 5 cells were seeded on 4-well chamber slides (NUNC). Cells were grown in Lab-Tek ® 4-well chamber slides. Cells were fixed in 4% phosphate buffered formaldehyde solution and stained using antibodies from Table S2 .
Whole transcript expression profiling, and gene-set enrichment analysis
Total RNA was isolated using the RNAeasy Kit (Qiagen), pooled and hybridized to GeneChip 
ATAC-seq
Chromatin accessibility mapping was performed using the ATAC-seq method as previously described 56 with minor adaptions. Duplicates of two different Stat3 fl and Stat3 ∆ cell lines were used for the assay. A volume containing 50.000 cells were harvested with the aid of an automated cell counter (TC20 Bio-Rad) and spun at 500g for 5 minutes at 4°C in PBS. After centrifugation, the pellet was carefully resuspended in the transposase reaction mix (12.5 µl 2xTD buffer, 2 µl TDE1 (Illumina), and 10.25 µl nuclease-free water, 0.25 µl 1% Digitonin (Sigma)) for 30 min at 37 °C. Following DNA purification with the MiniElute kit eluting in 12 µl, 1 µl of the eluted DNA was used in a quantitative PCR reaction to estimate the optimum number of amplification cycles. Library amplification was followed by SPRI size selection to exclude fragments larger than 1,200 bp. DNA and concentration was measured with a Qubit fluorometer (Life Technologies). Library amplification was performed using custom Nextera primers 57 . The libraries were sequenced by the Biomedical Sequencing Facility at CeMM using the Illumina HiSeq 3000/4000 platform and the 50-bp single-end configuration. Whole genome sequencing data was deposited at GEO (GSE119540).
Preprocessing and analysis of ATAC-seq data
ATAC-seq reads were trimmed using Skewer 58 and aligned to the GRCh37/hg19 assembly of the human genome using Bowtie2 59 with the '-very-sensitive' parameter. Duplicate reads were removed using the sambamba 60 'markdup' command, and reads with mapping quality >30 and alignment to the nuclear genome were kept. All downstream analyses were performed on these filtered reads. Genome browser tracks were created with the genomeCoverageBed command in BEDTools 61 and normalized such that each value represents the read count per base pair per million mapped and filtered reads. Finally, the UCSC Genome Browser's bedGraphToBigWig tool was used to produce a bigWig file. Peak calling was performed with MACS2 62 using the '-nomodel' and '-extsize 147' parameters, and peaks overlapping blacklisted features defined by the ENCODE project 63 were discarded. We created a consensus region set by merging the called peaks from all samples across cell lines, and we quantified the accessibility of each region in each sample by counting the number of reads from the filtered BAM file that overlapped each region. To normalize the chromatin accessibility signal across samples, we first performed quantile normalization using the R implementation in the preprocessCore package ('normalize.quantiles' function).
Statistics
All values are given as means±standard error of the mean (s.e.m.) or standard deviation (s.d.)
as indicated. Data were analyzed by GraphPad Prism ® 5. In vitro data, Western blots, RT-PCRs and viability assays were repeated at least three times. Scatter plots were calculated from the publically available GSE19234 and the TCGA study on cutaneous melanoma 64, 65 .
RNA expression data sets were generated with SPSS v21. Pearson correlation analysis was (Table S4) and a MITF pathway set comprised of 33 MITF targets (Table S5) 
